• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3 filed by new insider Needham Investment Management Llc

    4/6/26 3:56:54 PM ET
    $POCI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $POCI alert in real time by email
    SEC FORM 3SEC Form 3
    FORM 3UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number:3235-0104
    Estimated average burden
    hours per response:0.5
    1. Name and Address of Reporting Person*
    NEEDHAM INVESTMENT MANAGEMENT LLC

    (Last)(First)(Middle)
    250 PARK AVENUE, 10TH FLOOR

    (Street)
    NEW YORK NEW YORK 10117

    (City)(State)(Zip)

    UNITED STATES

    (Country)
    2. Date of Event Requiring Statement (Month/Day/Year)
    03/27/2026
    3. Issuer Name and Ticker or Trading Symbol
    PRECISION OPTICS CORPORATION, INC. [ POCI ]
    3a. Foreign Trading Symbol
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    DirectorX10% Owner
    Officer (give title below)Other (specify below)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    Form filed by One Reporting Person
    XForm filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Common Stock, par value $0.01 per share1,670,550D(1)
    Common Stock, par value $0.01 per share1,670,550I(1)By: Needham Investment Management L.L.C.
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year)3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date ExercisableExpiration DateTitleAmount or Number of Shares
    1. Name and Address of Reporting Person*
    NEEDHAM INVESTMENT MANAGEMENT LLC

    (Last)(First)(Middle)
    250 PARK AVENUE, 10TH FLOOR

    (Street)
    NEW YORK NEW YORK 10117

    (City)(State)(Zip)

    UNITED STATES

    (Country)

    Relationship of Reporting Person(s) to Issuer
    DirectorX10% Owner
    Officer (give title below)Other (specify below)
    1. Name and Address of Reporting Person*
    Needham Aggressive Growth Fund

    (Last)(First)(Middle)
    C/O NEEDHAM INVESTMENT MANAGEMENT L.L.C.
    250 PARK AVENUE, 10TH FLOOR

    (Street)
    NEW YORK NEW YORK 10177-1099

    (City)(State)(Zip)

    UNITED STATES

    (Country)

    Relationship of Reporting Person(s) to Issuer
    DirectorX10% Owner
    Officer (give title below)Other (specify below)
    Explanation of Responses:
    1. The reported securities are directly owned by Needham Aggressive Growth Fund, an investment advisory client of Needham Investment Management, L.L.C. ("NIM"), a Delaware limited liability company that is registered as an investment adviser with the Securities and Exchange Commission, and may be deemed to be indirectly beneficially owned by: (i) NIM; and (ii) George A. Needham as President and CEO of NIM. NIM and George A. Needham disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended or for any other purpose.
    Remarks:
    George A. Needham will be reported as a Reporting Person on a subsequent Form 3 made by NIM once CIK codes for George A. Needham are received.
    Needham Investment Management L.L.C., By: /s/ James W. Giangrasso, Chief Financial Officer04/06/2026
    Needham Aggressive Growth Fund, By: James W. Giangrasso, Chief Financial Officer04/06/2026
    ** Signature of Reporting PersonDate
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    * Form 3: SEC 1473 (03-26)
    Get the next $POCI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $POCI

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $POCI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Needham Investment Management Llc

    3 - PRECISION OPTICS CORPORATION, INC. (0000867840) (Issuer)

    4/6/26 3:56:54 PM ET
    $POCI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 4 filed by Coll Wayne M

    4 - PRECISION OPTICS CORPORATION, INC. (0000867840) (Issuer)

    4/2/26 4:15:18 PM ET
    $POCI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 4 filed by Traut Joseph

    4 - PRECISION OPTICS CORPORATION, INC. (0000867840) (Issuer)

    4/1/26 4:15:03 PM ET
    $POCI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $POCI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Precision Optics Corporation, Inc. Announces Pricing of Upsized $10 Million Public Offering of Common Stock

    GARDNER, Mass., March 27, 2026 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ:POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, today announced the pricing of its previously announced underwritten public offering of 2,777,777 shares of its common stock at a public offering price of $3.60 per share, before deducting underwriting discounts and commissions and offering expenses. The oversubscribed offering was led by a mix of existing and new fundamental institutional investors and included participation from directors, officers and executive management of the company including Dr. Joseph N. Forkey, th

    3/27/26 7:30:00 AM ET
    $POCI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Precision Optics Corporation, Inc. Announces Proposed Public Offering of Common Stock

    GARDNER, Mass., March 26, 2026 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ:POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, today announced that it is commencing an underwritten public offering of shares of its common stock (or common stock equivalents). The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Lucid Capital Markets is acting as the sole book-running manager for the offering. The offering is being made pursuant to a shelf registration statement on Form S-3 (

    3/26/26 4:01:00 PM ET
    $POCI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Precision Optics Reports Second Quarter Fiscal Year 2026 Financial Results

    GARDNER, Mass., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ:POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, announced operating results on an unaudited basis for its second quarter fiscal year 2026 for the period ended December 31, 2025. Q2 2026 Financial Highlights (3 Months Ended December 31, 2025): Revenue was $7.4 million, a quarterly record, compared to $4.5 million in the same quarter of the previous fiscal year, representing growth of approximately 63%, and compared to $6.7 million in the most recent sequential quarter.Production revenue was $6.4 million, a quarterly recor

    2/17/26 4:30:00 PM ET
    $POCI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $POCI
    SEC Filings

    View All

    Precision Optics Corporation Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits

    8-K - PRECISION OPTICS CORPORATION, INC. (0000867840) (Filer)

    3/30/26 5:34:38 PM ET
    $POCI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 424B5 filed by Precision Optics Corporation Inc.

    424B5 - PRECISION OPTICS CORPORATION, INC. (0000867840) (Filer)

    3/30/26 9:00:25 AM ET
    $POCI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 424B5 filed by Precision Optics Corporation Inc.

    424B5 - PRECISION OPTICS CORPORATION, INC. (0000867840) (Filer)

    3/26/26 4:01:15 PM ET
    $POCI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $POCI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Coll Wayne M bought $107,905,271 worth of shares (4,317 units at $24,995.43) (SEC Form 4)

    4 - PRECISION OPTICS CORPORATION, INC. (0000867840) (Issuer)

    8/16/24 4:30:31 PM ET
    $POCI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Chief Executive Officer Forkey Joseph Norman bought $17,228,869 worth of shares (1,725 units at $9,987.75), increasing direct ownership by 1% to 122,572 units (SEC Form 4)

    4 - PRECISION OPTICS CORPORATION, INC. (0000867840) (Issuer)

    8/16/24 4:30:30 PM ET
    $POCI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Chief Operating Officer Lawande Mahesh bought $17,248,850 worth of shares (1,726 units at $9,993.54) (SEC Form 4)

    4 - PRECISION OPTICS CORPORATION, INC. (0000867840) (Issuer)

    8/16/24 4:30:33 PM ET
    $POCI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $POCI
    Financials

    Live finance-specific insights

    View All

    Precision Optics Schedules Second Quarter of Fiscal Year 2026 Conference Call for February 17, 2026

    GARDNER, Mass., Feb. 13, 2026 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ:POCI) (the "Company"), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, today announced that it has scheduled a conference call to discuss the Company's second quarter fiscal year 2026 financial results on Tuesday, February 17, 2026, at 5:00 p.m. ET. The Company intends to release its financial results and to file its 10-Q after the close of the market on Tuesday, February 17, 2026, followed by the conference call. Conference Call Details Date and Time: Tuesday, February 17, 2026, at 5:00 p.m. ET. Call-in Information: Interest

    2/13/26 9:00:00 AM ET
    $POCI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Precision Optics Schedules First Quarter of Fiscal Year 2026 Conference Call for November 13, 2025

    GARDNER, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ:POCI) (the "Company"), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, today announced that it has scheduled a conference call to discuss the Company's first quarter fiscal year 2026 financial results on Thursday, November 13, 2025, at 5:00 p.m. ET. The Company intends to release its financial results and to file its 10-Q after the close of the market on Thursday, November 13, 2025, followed by the conference call. Conference Call Details Date and Time: Thursday, November 13, 2025, at 5:00 p.m. ET. Call-in Information: Intere

    11/6/25 4:15:00 PM ET
    $POCI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Precision Optics Schedules Fourth Quarter and Fiscal Year 2025 Conference Call for September 29, 2025

    GARDNER, Mass., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ:POCI) (the "Company"), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, today announced that it has scheduled a conference call to discuss the Company's fourth quarter and fiscal year 2025 financial results on Monday, September 29, 2025, at 5:00 p.m. ET. The Company intends to release its financial results and to file its 10-K after the close of the market on Monday, September 29, 2025, followed by the conference call. Conference Call Details Date and Time: Monday, September 29, 2025, at 5:00 p.m. ET. Call-in Information: Int

    9/24/25 4:15:00 PM ET
    $POCI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $POCI
    Leadership Updates

    Live Leadership Updates

    View All

    Precision Optics Appoints Joseph P. Pellegrino, Jr. to Board of Directors

    GARDNER, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ:POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, is pleased to announce the appointment of Joseph P. "JJ" Pellegrino, Jr. to its Board of Directors. Mr. Pellegrino, who will also serve as Chairman of the Board's Audit Committee, brings decades of operational and financial experience as well as an extensive knowledge of the medical device industry to the board. Mr. Pellegrino most recently served as Chief Financial Officer of LeMaitre Vascular, Inc. (NASDAQ:LMAT), a provider of devices, implants and services for the treatm

    3/20/25 9:00:00 AM ET
    $LMAT
    $POCI
    Medical/Dental Instruments
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus

    Precision Optics Appoints Buell Duncan to Board of Directors; Dr. Richard Miles Retires from Board

    GARDNER, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ:POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, is pleased to announce the appointment of Buell Duncan to its Board of Directors. Mr. Duncan brings decades of executive leadership and strategic expertise, further strengthening the Company's commitment to innovation and growth. With an extensive career in the technology and business sectors, Mr. Duncan held senior leadership positions at a number of IBM global business units from 1992 through 2020 where he was instrumental in driving marketing, strategy, and business deve

    3/4/25 4:30:00 PM ET
    $POCI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Precision Optics Appoints Clay Schwabe as VP of Sales and Marketing

    GARDNER, Mass., July 08, 2024 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ:POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense industries, today announced the appointment of Clay Schwabe, as the Company's Vice President of Sales and Marketing. Mr. Schwabe has over fifteen years of experience in medical device market access, sales, sales management, global product marketing, and commercialization. He is an emerging technologies specialist with experience in early-stage commercialization of minimally invasive surgical products and procedures. Most recently, he served as VP Business Development, Commercial Strategy, CRO, an

    7/8/24 9:00:00 AM ET
    $POCI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $POCI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Precision Optics Corporation Inc.

    SC 13G/A - PRECISION OPTICS CORPORATION, INC. (0000867840) (Subject)

    11/13/24 5:53:45 PM ET
    $POCI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G filed by Precision Optics Corporation Inc.

    SC 13G - PRECISION OPTICS CORPORATION, INC. (0000867840) (Subject)

    5/17/24 5:03:18 PM ET
    $POCI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care